Abstract:OBJECTIVE:(Background): Alzheimer's disease (AD), clinically characterized by the progressive neurodegenerative condition and cognitive impairment, is one of the main causes of disability in elder people worldwide. Recently, several animal studies indicated that the 'gut-brain' axis might contribute to the amyloid deposition of AD. However, data about gut dysbiosis in human AD remains scarce in the literature, especially including the whole process of AD. In this prospective and cross-sectional study, we aimed at identifying differences in microbiome between patients with AD (Pre-onset stage amnestic mild cognitive impairment, aMCI; and AD) and the normal cognition healthy controls (HC). Additionally, the potential association between IM and clinical characteristics of AD was evaluated.METHODS:A total of 97 subjects (33 AD, 32 aMCI, and 32 HC) were recruited in the study. The composition of gut bacterial communities was determined by 16S ribosomal RNA Miseq sequencing. In addition, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict function shift of intestinal microbiota. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) or Clinical Dementia Rating (CDR) scores were used to evaluate the severity of cognitive impairment in patients.RESULTS:The fecal microbial diversity was decreased in AD patients compared with aMCI patients and HC. And the microbial composition was distinct among aMCI, AD and healthy control groups. Among bacterial taxa, the proportion of phylum Firmicutes was significantly reduced (P = 0.008), whereas Proteobacteria (P = 0.024) was highly enriched in the AD compared with HC. In addition, similar alterations were observed at the order, class and family levels of these two phyla. And Gammaproteobacteria, Enterobacteriales and Enterobacteriaceae showed a progressive enriched prevalence from HC to aMCI and AD patients. Further, a significant correlation was observed between the clinical severity scores of AD patients and the abundance of altered microbiomes. Moreover, the KEGG results showed the increased modules related to glycan biosynthesis and metabolism in AD and aMCI patients and decreased pathways related to immune system in AD patients. Importantly, the discriminating models based on predominant microbiota could effectively distinguish aMCI and AD from HC (AUC = 0.890, 0.940, respectively), and also AD from aMCI (AUC = 0.925). Notably, the models based on the abundance of family Enterobacteriaceae could distinguish AD from both aMCI (AUC = 0.688) and HC (AUC = 0.698).CONCLUSIONS:Distinct microbial communities, especially enriched Enterobacteriaceae, were associated with patients with AD when compared with predementia stage aMCI and healthy subjects. These novel findings will give new clues to understand the disease and provide new therapeutic target for intervention or a marker for this disease.

Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study

Alteration and clinical potential in gut microbiota in patients with cerebral small vessel disease

The association between alpha diversity of gut microbiota, neuroimaging markers and cognitive function in cerebral small vessel disease

Multi-omics analysis of gut-brain axis reveals novel microbial and neurotransmitter signatures in patients with arteriosclerotic cerebral small vessel disease

The Relationship Between Amyloid Pathology, Cerebral Small Vessel Disease, Glymphatic Dysfunction, and Cognition: a Study Based on Alzheimer’s Disease Continuum Participants

Abstract TP15: Association Between Prevalent Cardiovascular Disease Plus Atrial Fibrillation and Global Cerebral Small Vessel Disease- The Framingham Heart Study

Altered Microbiomes Distinguish Alzheimer's Disease from Amnestic Mild Cognitive Impairment and Health in a Chinese Cohort.

Superficial White Matter Microstructure Affects Processing Speed in Cerebral Small Vessel Disease

Disruptions of Gut Microbiota Are Associated with Cognitive Deficit of Preclinical Alzheimer's Disease: A Cross-Sectional Study.

Poor cognition is associated with increased abundance of Alistipes and decreased abundance of Clostridium genera in the gut

Association of the Gut Microbiota With Cognitive Function in Midlife

Alterations of Gut Microbiota Are Associated with Brain Structural Changes in the Spectrum of Alzheimer's Disease: the SILCODE Study in Hainan Cohort

Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The SILCODE Study.

Abstract TP39: Multi-Marker Cerebral Small Vessel Disease Score and Risk of Incident Depression: The Framingham Heart Study

Abstract WMP16: Multi-Marker Cerebral Small Vessel Disease Score and Risk of Incident Dementia in the Framingham Heart Study

Higher burden of cerebral small vessel disease associated with risk of incident stroke in community dwelling individuals

Homocysteine is Associated with the Development of Cerebral Small Vessel Disease: Retrospective Analyses from Neuroimaging and Cognitive Outcomes

Mendelian Randomization Highlights Gut Microbiota of Short-chain Fatty Acids’ Producer as Protective Factor of Cerebrovascular Disease

Gut microbiota and intestinal barrier function in subjects with cognitive impairments: a cross-sectional study

A peripheral signature of Alzheimer's disease featuring microbiota-gut-brain axis markers

Metagenomic association analysis of cognitive impairment in community-dwelling older adults